Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1ALEMTUZUMAB1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-17件: 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284
2Alemtuzumab (already received by alemtuzumab cohort between 1991 and 19941件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 46
3Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 46
4Alemtuzumab (Campath )1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 60
5Alemtuzumab (Campath)1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 15
6Alemtuzumab (GZ402673)1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
7Alemtuzumab 0.2 mg1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-2件: 65, 164
8Alemtuzumab 0.3 mg1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-2件: 65, 164
9Alemtuzumab 12 mg1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
10Alemtuzumab 24 mg1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
11Alemtuzumab and Rituximab2件: Alemtuzumab,
Rituximab		2件: D02802 (Name: Alemtuzumab),
D02994 		2件: CD52,
MS4A1 💬		-1件: 60
12Alemtuzumab GZ4026731件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
13Alemtuzumab immunotherapy1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
14Alemtuzumab Injection1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
15Alemtuzumab Injection [Lemtrada]1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 13
16Alemtuzumab, Rituximab2件: Alemtuzumab,
Rituximab		2件: D02802 (Name: Alemtuzumab),
D02994 		2件: CD52,
MS4A1 💬		2件: , Hematopoietic cell lineage 💬1件: 63
17CAMPATH-1H (Alemtuzumab)1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 60
18Filgrastim, Alemtuzumab2件: Alemtuzumab,
Filgrastim		2件: D02802 (Name: Alemtuzumab),
D03235 		2件: CD52,
CSF3R 💬		6件: , Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 65
19Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab12件: Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		10件: D01370 ,
D02802 (Name: Alemtuzumab),
D02994 ,
D03846 ,
D05218 ,
D06886 ,
D09314 ,
D10001 ,
D10172 ,
D11215 		7件: CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬		31件: , Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬1件: 13
20Transplant Conditioning with Mobilization and Alemtuzumab1件: Alemtuzumab1件: D02802 (Name: Alemtuzumab)1件: CD52 💬-1件: 65
21Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan4件: Alemtuzumab,
Fludarabine,
Melphalan,
Thiotepa		4件: D00369 ,
D00583 ,
D02802 (Name: Alemtuzumab),
D07966 		2件: CD52,
RRM1 💬		-2件: 65, 164